The follow-up clinical studies on sotagliflozin: Novel quality in treatment of pathological heart conditions
Srce i krvni sudovi · 2026 · 45 (3) · 5-8
DOI: 10.5937/siks2601005r ↗Kurz gefasst
Fachartikel in der Zeitschrift Srce i krvni sudovi, 2026. Verfasst von Miroslav Radenković. Die Arbeit nennt 12 Literaturangaben. Gefördert von: Ministry of Education, Science and Technological Development of the Republic of Serbia.
Abstract (Originalsprache)
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are relatively novel glucose-lowering drugs that in addition promote improvement in metabolic syndrome and cardiovascular outcomes. Furthermore, the results of groundbreaking trials showed unequivocally that non-diabetic patients with chronic renal disease and/or heart failure with reduced ejection fraction benefited from novel SGLT2 inhibitors like sotagliflozin. Nevertheless, because SGLT2 inhibitors are known to cause adverse drug reactions, for each patient risks and benefits should be carefully considered before prescribing. Given the previous facts, the main goal of this paper was to offer up-to-date information about new clinical trials examining efficacy and safety of sotagliflozin in different cardiovascular pathologies. This may enhance comprehension of this novel pharmacotherapeutic agent for heart failure, hence assisting doctors in its appropriate prescription and effective clinical application.
Förderung
- Ministry of Education, Science and Technological Development of the Republic of Serbia
Zitieren
APA
Radenković, M. (2026). The follow-up clinical studies on sotagliflozin: Novel quality in treatment of pathological heart conditions. Srce i krvni sudovi, 45(3), 5-8. https://doi.org/10.5937/siks2601005r
Vancouver
Radenković M. The follow-up clinical studies on sotagliflozin: Novel quality in treatment of pathological heart conditions. Srce i krvni sudovi. 2026;45(3):5-8. doi:10.5937/siks2601005r
BibTeX
@article{Radenkovi2026,
author = {Radenković, Miroslav},
title = {The follow-up clinical studies on sotagliflozin: Novel quality in treatment of pathological heart conditions},
journal = {Srce i krvni sudovi},
year = {2026},
volume = {45},
number = {3},
pages = {5--8},
doi = {10.5937/siks2601005r}
}
EUVIMED